Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers
- 1 December 2008
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 111 (3) , 487-495
- https://doi.org/10.1016/j.ygyno.2008.08.020
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- p53 and its isoforms in cancerBritish Journal of Cancer, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studiesBritish Journal of Cancer, 2006
- p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: A multivariate analysisGynecologic Oncology, 2005
- Twenty years of p53 research: structural and functional aspects of the p53 proteinOncogene, 1999
- Quantification of p53 in Epithelial Ovarian CancerGynecologic Oncology, 1997
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Characterisation of Epitopes on Human p53 using Phage-displayed Peptide Libraries: Insights into Antibody-Peptide InteractionsJournal of Molecular Biology, 1995
- P53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significanceEuropean Journal Of Cancer, 1994
- High Incidence of p53 Gene Mutation in Human Ovarian Cancer and Its Association with Nuclear Accumulation of p53 Protein and Tumor DNA AneuploidyJapanese Journal of Cancer Research, 1992